JP5992525B2 - 高度に生物学的に利用可能なゼロ価硫黄の調製及び組成物並びにその使用 - Google Patents

高度に生物学的に利用可能なゼロ価硫黄の調製及び組成物並びにその使用 Download PDF

Info

Publication number
JP5992525B2
JP5992525B2 JP2014530618A JP2014530618A JP5992525B2 JP 5992525 B2 JP5992525 B2 JP 5992525B2 JP 2014530618 A JP2014530618 A JP 2014530618A JP 2014530618 A JP2014530618 A JP 2014530618A JP 5992525 B2 JP5992525 B2 JP 5992525B2
Authority
JP
Japan
Prior art keywords
composition
sulfur
sodium
tac
highly polar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014530618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532042A (ja
Inventor
ロマニージョス，ガブリエル ゴジョン
ロマニージョス，ガブリエル ゴジョン
ソリージャ，ガブリエル ゴジョン
ソリージャ，ガブリエル ゴジョン
Original Assignee
ヌエヴァス オルタナティヴァス ナチュラルズ，エス．エー．ピー．アイ．デ シー．ブイ．
ヌエヴァス オルタナティヴァス ナチュラルズ，エス．エー．ピー．アイ．デ シー．ブイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヌエヴァス オルタナティヴァス ナチュラルズ，エス．エー．ピー．アイ．デ シー．ブイ．, ヌエヴァス オルタナティヴァス ナチュラルズ，エス．エー．ピー．アイ．デ シー．ブイ． filed Critical ヌエヴァス オルタナティヴァス ナチュラルズ，エス．エー．ピー．アイ．デ シー．ブイ．
Publication of JP2014532042A publication Critical patent/JP2014532042A/ja
Application granted granted Critical
Publication of JP5992525B2 publication Critical patent/JP5992525B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
JP2014530618A 2011-09-14 2012-09-13 高度に生物学的に利用可能なゼロ価硫黄の調製及び組成物並びにその使用 Expired - Fee Related JP5992525B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161534585P 2011-09-14 2011-09-14
US61/534,585 2011-09-14
PCT/MX2012/000086 WO2013055199A1 (es) 2011-09-14 2012-09-13 Preparación y composiciones de azufre con valencia cero. altamente biq-disponibles y sus usos

Publications (2)

Publication Number Publication Date
JP2014532042A JP2014532042A (ja) 2014-12-04
JP5992525B2 true JP5992525B2 (ja) 2016-09-14

Family

ID=47830038

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014530618A Expired - Fee Related JP5992525B2 (ja) 2011-09-14 2012-09-13 高度に生物学的に利用可能なゼロ価硫黄の調製及び組成物並びにその使用
JP2014530796A Pending JP2014526511A (ja) 2011-09-14 2012-09-13 高度に生物学的に利用可能なゼロ価硫黄の調製及び組成物並びにその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014530796A Pending JP2014526511A (ja) 2011-09-14 2012-09-13 高度に生物学的に利用可能なゼロ価硫黄の調製及び組成物並びにその使用

Country Status (11)

Country Link
US (3) US8771755B2 (enExample)
EP (2) EP2756757B1 (enExample)
JP (2) JP5992525B2 (enExample)
CN (2) CN104080334A (enExample)
AU (3) AU2012321444B2 (enExample)
BR (3) BR112014005144B1 (enExample)
CA (2) CA2847589C (enExample)
ES (1) ES2739628T3 (enExample)
HK (1) HK1200278A1 (enExample)
MX (3) MX360050B (enExample)
WO (2) WO2013055199A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541396B2 (en) 2009-04-24 2013-09-24 National University Of Singapore Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent
US9306218B2 (en) 2011-08-11 2016-04-05 Arizona Board Of Regents On Behalf Of The University Of Arizona High sulfur content copolymers and composite materials and electrochemical cells and optical elements using them
US11795248B2 (en) 2011-08-11 2023-10-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Copolymerization of elemental sulfur and epoxy functional styrenics
US11015023B2 (en) 2011-08-11 2021-05-25 Arizona Board Of Regents On Behalf Of The University Of Arizona Fire retardant compositions utilizing elemental sulfur
US10920020B2 (en) 2011-08-11 2021-02-16 Arizona Board Of Regents On Behalf Of The University Of Arizona 3D-printing of ultra-high refractive index polymers
US9567439B1 (en) 2011-08-11 2017-02-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Sulfur composites and polymeric materials from elemental sulfur
HK1200278A1 (en) * 2011-09-14 2015-08-07 Nuevas Alternativas Naturales, S.A.P.I. de C.V. Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof
US10894863B2 (en) 2014-02-14 2021-01-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Cathode materials for Li—S batteries
KR20160122838A (ko) * 2014-02-14 2016-10-24 더 아리조나 보드 오브 리전츠 온 비해프 오브 더 유니버시티 오브 아리조나 원소 황에서 유래된 황 복합체 및 폴리머 재료
US9795676B2 (en) 2014-03-03 2017-10-24 Shayne Kenneth Morris Chromium 4-hydroxyisoleucinate compound methods for prepartion and use
EP3151671A4 (en) * 2014-06-03 2018-03-07 Sulfagenix, Inc. Methods and compositions for treating nitric oxide deficiency disorders and related conditions
JP6806965B2 (ja) * 2014-07-29 2021-01-06 国立大学法人 筑波大学 精子機能改善剤とこれを含む医薬品組成物、飼料、食品組成物及び家畜または家禽の精子機能改善方法
WO2016159612A1 (ko) * 2015-03-27 2016-10-06 서울대학교산학협력단 폴리설파이드 공중합체 나노입자 및 그의 제조 방법
US11078333B2 (en) 2015-07-13 2021-08-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Copolymerization of elemental sulfur to synthesize high sulfur content polymeric materials
US10238685B2 (en) * 2015-12-02 2019-03-26 Johnson & Johnson Consumer Inc. Compositions containing polymeric sulfur and uses thereof
US20170252369A1 (en) * 2016-03-03 2017-09-07 Frederick J. Sawaya Method for treating parkinson disease, neurodegenerative disorders, and autoimmune diseases
CN107281215A (zh) * 2016-04-01 2017-10-24 复旦大学附属妇产科医院 硫化氢供体硫氢化钠在制药中的用途
WO2018107169A1 (en) 2016-12-09 2018-06-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Metallopolymers for catalytic generation of hydrogen
JP6989157B2 (ja) * 2017-02-09 2022-01-05 ノクサノ インコーポレイテッド 電気化学ガス状伝達物質生成組成物及びその使用方法ならびにそれを組み込んだ被覆材及び治療システム
US20180271823A1 (en) * 2017-03-23 2018-09-27 Washington State University Sulfur-based broad spectrum antivirals
US11674005B2 (en) 2017-06-15 2023-06-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Chalcogenide Hybrid Inorganic/organic Polymer (CHIP) materials as improved crosslinking agents for vulcanization
FR3072024A1 (fr) * 2017-10-11 2019-04-12 Olivier Petitjean Prevention et traitement de l’hyperplasie benigne de la prostate a l‘aide d’un inhibiteur selectif de la production d’especes reactives de l’oxygene d’origine mitochondriale
CN108486081B (zh) * 2018-05-04 2021-07-02 山西大学 一种植物巯基丙酮酸硫转移酶及其应用
WO2020046635A1 (en) * 2018-08-28 2020-03-05 The Regents Of The University Of California Tetrathionate for cyanide and methylmercaptan poisoning
WO2021092392A1 (en) * 2019-11-07 2021-05-14 Cornell University Use of membrane inhibitors to enhance vaccine development against enveloped viruses
WO2021226037A1 (en) * 2020-05-04 2021-11-11 Sulfagenix, Inc. Treatment of viral infections
FR3125409A1 (fr) * 2021-07-26 2023-01-27 Nuribiol Complément alimentaire permettant de lutter contre l’infertilité féminine et masculine
IT202100021548A1 (it) * 2021-08-09 2023-02-09 Universita’ Di Pisa Coniugati della metformina e loro impiego terapeutico
WO2023079466A2 (en) * 2021-11-03 2023-05-11 Sulfagenix, Inc. Treatment of sequelae of coronavirus infections
EP4212149A1 (en) 2022-01-18 2023-07-19 Rijksuniversiteit Groningen Oral dosage forms of acid-labile salt and methods and uses related thereto
WO2024127426A1 (en) * 2022-12-12 2024-06-20 Polishetty Ravishankar An herbal formulation prs-01 for regeneration of the cardiomyocytes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1213050B (it) * 1986-03-14 1989-12-07 Schiena Ricerche Composizioni farmaceutiche topiche in odontostomatologia contenenti allantoina e zolfo elementare
US5100653A (en) * 1991-02-08 1992-03-31 Giovanni Campo Topical compositions for treating mouth tissues
US6855342B2 (en) * 2000-06-30 2005-02-15 Medicis Pharmaceutical Corporation Compositions and methods for high sorption of skin materials and delivery of sulfur
US6514489B1 (en) * 2000-06-30 2003-02-04 Medicis Pharmaceutical Corp. Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions
AUPS255402A0 (en) * 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with oxidative stress
US8361514B2 (en) * 2002-06-19 2013-01-29 Nuevas Alternatives Naturales Thermafat, S.A.P.I. de C.V. Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
US20030235571A1 (en) 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
CN1320925C (zh) * 2005-03-30 2007-06-13 淮北市辉克药业有限公司 长期使用的治疗糖尿病的复方制剂
US7741359B2 (en) 2005-05-27 2010-06-22 Antibe Therapeutics Inc. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
US20100172992A1 (en) * 2006-06-02 2010-07-08 Natural Ma Inc. Pathogenic attenuation via the administration of an equilibiotic compound
US7923037B2 (en) 2006-10-05 2011-04-12 Ikaria, Inc. Liquid chalcogenide compositions and methods of manufacturing and using the same
US20120135091A1 (en) * 2007-01-18 2012-05-31 Roth Mark B Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
EP2170356A1 (en) * 2007-06-25 2010-04-07 Fred Hutchinson Cancer Research Center Methods and compositions regarding polychalcogenide compositions
EP2167068A2 (en) 2007-07-05 2010-03-31 Inserm-Institut National De La Sante Et De La Recherche Medicale Anticonvulsive pharmaceutical compositions
CN101467991B (zh) * 2007-08-02 2012-02-01 复旦大学 烯丙基半胱氨酸及其类似物在制备治疗心肌损伤药物中的用途
US20110172171A1 (en) 2008-09-12 2011-07-14 Serge Picaud Taurine or taurine-like substances for the prevention of brain oedema
RU2406477C1 (ru) 2009-08-25 2010-12-20 Федеральное государственное учреждение "Научно-исследовательский центр курортологии и реабилитации Федерального агентства по здравоохранению и социальному развитию" (ФГУ "НИЦКиР Росздрава") Способ лечения ишемической болезни сердца, стенокардии напряжения i-ii функциональных классов
US8680151B2 (en) * 2010-02-11 2014-03-25 Fred Hutchinson Cancer Research Center Compounds, compositions and methods for treating or preventing hypoxic or ischemic injury
WO2012075242A2 (en) 2010-12-01 2012-06-07 Washington State University Research Foundation Controlled chemical release of hydrogen sulfide
HK1200278A1 (en) * 2011-09-14 2015-08-07 Nuevas Alternativas Naturales, S.A.P.I. de C.V. Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof

Also Published As

Publication number Publication date
BR112014005144A2 (pt) 2017-04-18
MX2014003289A (es) 2016-05-16
EP2756757A1 (en) 2014-07-23
MX386642B (es) 2025-03-19
BR112014004859A2 (pt) 2017-06-13
EP2755478A1 (en) 2014-07-23
US20130064904A1 (en) 2013-03-14
US20140322361A1 (en) 2014-10-30
CN104080334A (zh) 2014-10-01
AU2012321444A1 (en) 2014-05-01
CN104080339A (zh) 2014-10-01
AU2015210403A1 (en) 2015-09-03
JP2014526511A (ja) 2014-10-06
US8771755B2 (en) 2014-07-08
BR122020020392B1 (pt) 2021-09-08
AU2012308501A2 (en) 2014-04-17
EP2755478A4 (en) 2015-06-10
JP2014532042A (ja) 2014-12-04
HK1200277A1 (en) 2015-08-07
HK1200278A1 (en) 2015-08-07
AU2012308501A1 (en) 2014-03-13
MX2014003288A (es) 2017-03-09
EP2756757A4 (en) 2015-05-20
EP2756757B1 (en) 2019-04-24
AU2012321444B2 (en) 2015-06-11
CA2847589A1 (en) 2013-04-18
US20150064286A1 (en) 2015-03-05
AU2012321444A2 (en) 2014-05-15
CA2847589C (en) 2019-11-26
MX360050B (es) 2018-10-19
ES2739628T3 (es) 2020-02-03
BR112014005144B1 (pt) 2021-06-08
WO2013055199A1 (es) 2013-04-18
WO2013040240A1 (en) 2013-03-21
AU2015210403B2 (en) 2016-11-24
CA2847264A1 (en) 2013-03-21
CN104080339B (zh) 2016-09-28

Similar Documents

Publication Publication Date Title
JP5992525B2 (ja) 高度に生物学的に利用可能なゼロ価硫黄の調製及び組成物並びにその使用
US8318805B2 (en) Modulation of nitric oxide synthases by betaines
Ri et al. Boron-containing compounds for prevention, diagnosis, and treatment of human metabolic disorders
CA2898596A1 (en) Compositions for the systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
US20100099757A1 (en) Disulfiram doses and treatment regimen suitable for treatment of angiogenesis-dependent disorders
US6703380B2 (en) Prevention of cancer
AU2004255405A1 (en) Herbal compositions for the treatment and prevention of prostate disorders
ES2344510T3 (es) Composicion que comprende l-serina, l-isoleucina, acido folico y elementos traza, para tratar la psoriasis.
HK1200277B (en) Preparation and compositions of zero-valent sulphur having high bioavailability, and uses thereof
Rangone Anticancer activity of multifunctional Pt (IV) prodrugs
KR101430293B1 (ko) 백금 나노입자를 포함하는 골다공증 치료 또는 예방용 조성물
Miceli Oleuropein aglycone induces protective autophagy: molecular mechanisms and therapeutic targets in pathological models of autophagy dysfunction.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140811

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160126

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160719

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160817

R150 Certificate of patent or registration of utility model

Ref document number: 5992525

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250